IP Library Granted Patent US 10,774,368
Granted Patent B2
US 10,774,368 · App. 16/176,210 · Granted Sep 15, 2020

Nucleic acid preservation solution and methods of manufacture and use

Inventor: Federico Carlos Arejola Gaeta (Torre Molinos, ES)
Assignee: Spectrum Solutions L.L.C.
C12Q1/6806C12N15/1003
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,774,368
App. No.
16/176,210
Granted
Sep 15, 2020
Kind
B2
Abstract

Disclosed is nucleic acid preserving compositions and methods of manufacturing and using the same. Compositions include a carrier, a chaotropic agent, a buffering agent, a chelating agent, a surfactant, an alcohol, an acid, and a mucolytic agent. Compositions as aqueous solutions can include water as a carrier. Preferred embodiments include water, guanidine thiocyanate, Tris, EDTA, SLS, SDA 3C, HCl, and N-acetyl-L-cysteine. Some embodiments include a colored dye as a visual indicator. Methods of manufacturing include combining the components into a mixture, such as an aqueous solution. Methods of use include providing a biological sample that includes nucleic acid and contacting the biological sample with the composition. Kits include the composition disposed in a portion of a biological sample collection apparatus.

Claims (88)

1. A nucleic acid preservation composition, comprising:

a carrier;

20-50%, w/w, of a chaotropic agent;

1-5%, w/w, of a buffering agent;

0.05-2.5%, w/w, of a chelating agent;

0.05-2.5%, w/w, of a detergent or a surfactant;

5-25%, w/w, of an alcohol; and

0.005-0.25%, w/w, of a mucolytic agent or a reducing agent, the composition having a pH of 7.2-8.8.

2. The composition of claim 1 , wherein the composition has a pH of 7.5-8.5.

3. The composition of claim 1 , wherein the composition has a pH of 7.8-8.2.

4. The composition of claim 1 , wherein the composition is substantially free or devoid of antimicrobial agent(s), bactericidal agent(s), and/or bacteriostatic agent(s) other than the chaotropic agent, the detergent or surfactant, the alcohol, and the mucolytic agent or reducing agent.

5. The composition of claim 1 , wherein the composition is substantially free or devoid of inhibitor(s) of ribonuclease other than the chaotropic agent, the detergent or surfactant, the alcohol, and the mucolytic agent or reducing agent.

6. The composition of claim 1 , wherein the composition is substantially free or devoid of protease(s).

7. The composition of claim 1 , wherein the alcohol comprises a mixture of about 95% ethanol, v/v, and about 5% isopropanol, v/v.

8. The composition of claim 1 , wherein:

the chaotropic agent comprises guanidine thiocyanate;

the buffering agent comprises tris(hydroxymethyl)aminomethane (Tris);

the chelating agent comprises ethylenediaminetetraacetic acid (EDTA) or EDTA disodium (salt) dihydrate;

the detergent or surfactant comprises sodium lauroyl sarcosinate (SLS);

the alcohol comprises ethanol; and

the mucolytic agent or reducing agent comprising N-acetyl-L-cysteine (NAC); and

the carrier comprising filtered, purified, distilled, and/or deionized water.

9. The composition of claim 1 , wherein the composition comprises:

39.53%-48.31%, w/w, of the chaotropic agent;

2.39%-2.92%, w/w, of the buffering agent;

0.73%-0.89%, w/w, of the chelating agent;

0.251%-0.307%, w/w, of the detergent or surfactant;

15.96%-19.50%, w/w, of the alcohol; and

0.084%-0.102%, w/w, of the mucolytic agent or reducing agent.

10. The composition of claim 9 , wherein:

the chaotropic agent comprises guanidine thiocyanate;

the buffering agent comprises tris(hydroxymethyl)aminomethane (Tris);

the chelating agent comprises ethylenediaminetetraacetic acid (EDTA) or EDTA disodium (salt) dihydrate;

the detergent or surfactant comprises sodium lauroyl sarcosinate (SLS);

the alcohol comprises ethanol;

the mucolytic agent or a reducing agent comprising N-acetyl-L-cysteine (NAC); and

the carrier comprising filtered, purified, distilled, and/or deionized water.

11. The composition of claim 1 , wherein the composition comprises:

43.48%-44.36%, w/w, of the chaotropic agent;

2.62%-2.68%, w/w, of the buffering agent;

0.80%-0.82%, w/w, of the chelating agent;

0.276%-0.282%, w/w, of the detergent or surfactant;

17.55%-17.91%, w/w, of the alcohol; and

0.092%-0.094%, w/w, of the mucolytic agent or reducing agent.

12. The composition of claim 11 , wherein:

the chaotropic agent comprises guanidine thiocyanate;

the buffering agent comprises tris(hydroxymethyl)aminomethane (Tris);

the chelating agent comprises ethylenediaminetetraacetic acid (EDTA) or EDTA disodium (salt) dihydrate;

the detergent or surfactant comprises sodium lauroyl sarcosinate (SLS);

the alcohol comprises ethanol;

the mucolytic agent or a reducing agent comprising N-acetyl-L-cysteine (NAC); and

the carrier comprising filtered, purified, distilled, and/or deionized water.

13. A nucleic acid preservation kit, comprising:

a sample collection apparatus comprising a solution compartment; and

the nucleic acid preservation composition of claim 1 disposed in the solution compartment.

14. A nucleic acid preservation kit, comprising:

a sample collection apparatus comprising a solution compartment; and

the nucleic acid preservation composition of claim 2 disposed in the solution compartment.

15. A nucleic acid preservation kit, comprising:

a sample collection apparatus comprising a solution compartment; and

the nucleic acid preservation composition of claim 3 disposed in the solution compartment.

16. A nucleic acid preservation kit, comprising:

a sample collection apparatus comprising a solution compartment; and

the nucleic acid preservation composition of claim 4 disposed in the solution compartment.

17. A nucleic acid preservation kit, comprising:

a sample collection apparatus comprising a solution compartment; and

the nucleic acid preservation composition of claim 5 disposed in the solution compartment.

18. A nucleic acid preservation kit, comprising:

a sample collection apparatus comprising a solution compartment; and

the nucleic acid preservation composition of claim 6 disposed in the solution compartment.

19. A nucleic acid preservation kit, comprising:

a sample collection apparatus comprising a solution compartment; and

the nucleic acid preservation composition of claim 7 disposed in the solution compartment.

20. A nucleic acid preservation kit, comprising:

a sample collection apparatus comprising a solution compartment; and

the nucleic acid preservation composition of claim 8 disposed in the solution compartment.

21. A nucleic acid preservation kit, comprising:

a sample collection apparatus comprising a solution compartment; and

the nucleic acid preservation composition of claim 9 disposed in the solution compartment.

22. A nucleic acid preservation kit, comprising:

a sample collection apparatus comprising a solution compartment; and

the nucleic acid preservation composition of claim 10 disposed in the solution compartment.

23. A nucleic acid preservation kit, comprising:

a sample collection apparatus comprising a solution compartment; and

the nucleic acid preservation composition of claim 11 disposed in the solution compartment.

24. A nucleic acid preservation kit, comprising:

a sample collection apparatus comprising a solution compartment; and

the nucleic acid preservation composition of claim 12 disposed in the solution compartment.

Assignments (5)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Apr 18, 2023
From: GAETA, FEDERICO CARLOS AREJOLA
To: SPECTRUM SOLUTIONS L.L.C.
Reel/Frame 063362/0263 →
RELEASE OF SECURITY INTEREST Recorded Mar 11, 2021
From: JPMORGAN CAHSE BANK, N.A.
To: SPECTRUM SOLUTIONS L.L.C.
Reel/Frame 055565/0282 →
SECURITY INTEREST Recorded Mar 5, 2021
From: SPECTRUM SOLUTIONS L.L.C.
To: TWIN BROOK CAPITAL PARTNERS, LLC, AS AGENT
Reel/Frame 055503/0673 →
SECURITY INTEREST Recorded May 20, 2019
From: SPECTRUM SOLUTIONS L.L.C.
To: JPMORGAN CHASE BANK, N.A.
Reel/Frame 049235/0813 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Oct 31, 2018
From: GAETA, FEDERICO CARLOS AREJOLA
To: SPECTRUM SOLUTIONS L.L.C.
Reel/Frame 047369/0518 →
Continuity (3)
Continuation 15872791 · Jan 16, 2018
Provisional Application 62446818 · Jan 16, 2017
Related Publication 20190062806A1 · Feb 28, 2019
Cited By (1)
US 12,390,808